Table 9.

γδ T cell-based cancer immunotherapies

Classification	Targets/Cells	Agents	Preclinical models or clinical trials
γδ T cell engagers	TRGV9/HER2	(Her2)2xVγ9	Preclinical pancreatic cancer model
	TRGV9/EGFR	LAVA-1223	Preclinical colon cancer model
	TRGV9/CD1d	LAVA-051	Leukemia and MM (NCT04887259)
	TRGV9/CD40	LAVA-1278	Preclinical MM model
	TRGV9/CD123	LAVA-1266	Preclinical AML model
	BTN3A	ICT01	Solid and hematological malignancies (NCT04243499 and NCT05307874)
Expanded γδ T cell transfer	Allogeneic Vγ9Vδ2 T cells	Unnamed product	Lung and liver cancers (NCT03183232 and NCT03183219)
	Allogeneic Vδ1 T (DOT) cells	GDX012	AML (NCT05001451)
	MGMT-modified γδ T cells	INB200	Glioblastoma (NCT04165941)
γδTCR-engineered T cell transfer	Vγ9Vδ2 TCR-engineered αβ T cells	TEG002	MM (NCT04688853)
	αβ T cells with anti-CD19 AbTCR	ET190L1	Lymphoma (NCT03415399)
	αβ T cells with anti-α-fetoprotein AbTCR and glypican-3-targeted co-stimulatory molecule	ET140203	HCC (NCT04502082 and NCT04634357)
CAR-γδ T cells	NKG2DL-targeting CAR-γδ T cells	CTM-N2D	Solid tumors (NCT04107142)
	CD20-targeting CAR-γδ T cells	ADI-001	B Cell Malignancies (NCT04735471 and NCT04911478)
	Glypican-3-targeting CAR-γδ T cells expressing soluble IL-15	ADI-002	Preclinical HCC model
	CD19-targeting CAR-γδ T cells	Unnamed product	Preclinical CD19+ leukemia model
	MUC1-Tn-targeting CAR-γδ T cells	Unnamed product	Preclinical gastric cancer model
	CD123-targeting CAR-DOT cells	Unnamed product	Preclinical AML model

MM multiple myeloma, AML acute myeloid leukemia, MGMT methylguanine DNA methyltransferase, HCC hepatocellular carcinoma, TCR T cell receptor, DOT Delta One T, TCR T cell receptor, CAR chimeric antigen receptor